

# Ruth Ann Marrie

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3284007/publications.pdf>

Version: 2024-02-01

421  
papers

23,904  
citations

12303

69  
h-index

10708

138  
g-index

424  
all docs

424  
docs citations

424  
times ranked

17481  
citing authors

#	ARTICLE	IF	CITATIONS
1	A Systematic Review of the Validity and Reliability of the Patient-Determined Disease Steps Scale. <i>International Journal of MS Care</i> , 2023, 25, 20-25.	0.4	4
2	Physical Activity and Sedentary Behavior Patterns Across Weekdays and Weekend Days in Youth With Multiple Sclerosis and Controls. <i>International Journal of MS Care</i> , 2022, 24, 8-12.	0.4	0
3	Factors Associated With Social Participation in Persons Living With Inflammatory Bowel Disease. <i>Journal of the Canadian Association of Gastroenterology</i> , 2022, 5, 59-67.	0.1	2
4	Childhood Maltreatment and Psychiatric Comorbidity in Immune-Mediated Inflammatory Disorders. <i>Psychosomatic Medicine</i> , 2022, 84, 10-19.	1.3	15
5	A Population-based Study of Grade 12 Academic Performance in Adolescents With Childhood-onset Chronic Rheumatic Diseases. <i>Journal of Rheumatology</i> , 2022, 49, 299-306.	1.0	1
6	Administrative data for observational research in multiple sclerosis: Opportunities and challenges. <i>Multiple Sclerosis Journal</i> , 2022, 28, 3-6.	1.4	2
7	Charting a global research strategy for progressive MS—An international progressive MS Alliance proposal. <i>Multiple Sclerosis Journal</i> , 2022, 28, 16-28.	1.4	5
8	Incidence of neurological and psychiatric comorbidity over time: a population-based cohort study in Ontario, Canada. <i>Age and Ageing</i> , 2022, 51, .	0.7	2
9	Metagenomic Analysis of the Pediatric-Onset Multiple Sclerosis Gut Microbiome. <i>Neurology</i> , 2022, 98, .	1.5	15
10	Development of an indicator of smoking status for people with multiple sclerosis in administrative data. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2022, 8, 205521732210742.	0.5	1
11	High or increasing serum NfL is predictive of impending multiple sclerosis relapses. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 59, 103535.	0.9	18
12	The health-related quality of life of children with multiple sclerosis is mediated by the health-related quality of life of their parents. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1299-1310.	1.4	4
13	Associations between courses of posttraumatic stress disorder and physical health conditions among Canadian military personnel. <i>Journal of Anxiety Disorders</i> , 2022, 87, 102543.	1.5	4
14	Control charts for chronic disease surveillance: testing algorithm sensitivity to changes in data coding. <i>BMC Public Health</i> , 2022, 22, 406.	1.2	0
15	Stability of the gut microbiota in persons with paediatric-onset multiple sclerosis and related demyelinating diseases. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1819-1824.	1.4	2
16	Pathways to cures for multiple sclerosis: A research roadmap. <i>Multiple Sclerosis Journal</i> , 2022, 28, 331-345.	1.4	9
17	Emergency department use by persons with MS: A population-based descriptive study with a focus on infection-related visits. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1825-1828.	1.4	1
18	Mesenchymal stem cell therapy and cognition in MS: Preliminary findings from a phase II clinical trial. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 61, 103779.	0.9	2

#	ARTICLE	IF	CITATIONS
19	Progressive retinal changes in pediatric multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 61, 103761.	0.9	2
20	Disease-modifying drugs for multiple sclerosis and subsequent health service use. <i>Multiple Sclerosis Journal</i> , 2022, 28, 583-596.	1.4	6
21	Use of Benzodiazepines and Z-Drugs in Multiple Sclerosis. <i>Frontiers in Neurology</i> , 2022, 13, 874724.	1.1	4
22	Depressive symptom trajectories and polygenic risk scores in individuals with an immune-mediated inflammatory disease. <i>General Hospital Psychiatry</i> , 2022, 77, 21-28.	1.2	5
23	Multiple Sclerosis and the Cancer Diagnosis. <i>Neurology</i> , 2022, 98, .	1.5	7
24	The metabolic potential of the paediatric-onset multiple sclerosis gut microbiome. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 63, 103829.	0.9	8
25	Serum MOG-IgG in children meeting multiple sclerosis diagnostic criteria. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1697-1709.	1.4	12
26	Attitudes toward coronavirus disease 2019 vaccination in people with multiple sclerosis. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2022, 8, 205521732211020.	0.5	4
27	Effects of Vascular Comorbidity on Cognition in Multiple Sclerosis Are Partially Mediated by Changes in Brain Structure. <i>Frontiers in Neurology</i> , 2022, 13, .	1.1	11
28	Models of Care in Multiple Sclerosis: A Survey of Canadian Health Providers. <i>Frontiers in Neurology</i> , 2022, 13, .	1.1	10
29	Disease-Modifying Drugs for Multiple Sclerosis and Association With Survival. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2022, 9, .	3.1	11
30	From the prodromal stage of multiple sclerosis to disease prevention. <i>Nature Reviews Neurology</i> , 2022, 18, 559-572.	4.9	23
31	Effect of mood and anxiety disorders on health care utilization in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1411-1420.	1.4	6
32	Anxiety and depression affect performance on the symbol digit modalities test over time in MS and other immune disorders. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1284-1292.	1.4	13
33	Rationale and Methodology of the 2018 Canadian Armed Forces Members and Veterans Mental Health Follow-up Survey (CAFVMHS): A 16-year Follow-up Survey: Raison D'être Et Méthodologie De L'enquête De Suivi Sur La Santé Mentale Des Membres Des Forces Armées Canadiennes Et Des Anciens Combattants. 2018 (ESSMEFACM). <i>Canadian Journal of Psychiatry</i> , 2021, 66, 942-950.	0.9	12
34	Data harmonization for collaborative research among MS registries: A case study in employment. <i>Multiple Sclerosis Journal</i> , 2021, 27, 281-289.	1.4	17
35	Adherence to laboratory monitoring among people taking oral drugs for multiple sclerosis: A Canadian population-based study. <i>Multiple Sclerosis Journal</i> , 2021, 27, 239-249.	1.4	5
36	Fatigue, sleep disorders, anaemia and pain in the multiple sclerosis prodrome. <i>Multiple Sclerosis Journal</i> , 2021, 27, 290-302.	1.4	33

#	ARTICLE	IF	CITATIONS
37	The multiple sclerosis prodrome: Emerging evidence, challenges, and opportunities. <i>Multiple Sclerosis Journal</i> , 2021, 27, 6-12.	1.4	50
38	New applications for independent activities of daily living in measuring disability in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 97-106.	1.4	5
39	Prevalence and Risk Factors of Substance Use Disorder in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 58-64.	0.9	12
40	Impact of Psychiatric Comorbidity on Health Care Use in Rheumatoid Arthritis: A Population-Based Study. <i>Arthritis Care and Research</i> , 2021, 73, 90-99.	1.5	6
41	Anxiety and Depression Leads to Anti-Tumor Necrosis Factor Discontinuation in Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1200-1208.e1.	2.4	18
42	Cancer Incidence and Mortality Rates in Multiple Sclerosis. <i>Neurology</i> , 2021, 96, e501-e512.	1.5	33
43	Characteristics of a population-based multiple sclerosis cohort treated with disease-modifying drugs in a universal healthcare setting. <i>Expert Review of Neurotherapeutics</i> , 2021, 21, 131-140.	1.4	11
44	Neuregulin-1 beta 1 is implicated in pathogenesis of multiple sclerosis. <i>Brain</i> , 2021, 144, 162-185.	3.7	11
45	The Relationship Between Symptoms of Depression and Anxiety and Disease Activity in IBD Over Time. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 1285-1293.	0.9	64
46	Short-term laboratory and related safety outcomes for the multiple sclerosis oral disease-modifying therapies: an observational study. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 481-487.	1.0	2
47	Comparative responsiveness of the health utilities index and the RAND-12 for multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1781-1789.	1.4	4
48	A propensity-matched comparison of long-term disability worsening in patients with multiple sclerosis treated with dimethyl fumarate or fingolimod. <i>Therapeutic Advances in Neurological Disorders</i> , 2021, 14, 175628642110211.	1.5	5
49	Medication adherence in multiple sclerosis as a potential model for other chronic diseases: a population-based cohort study. <i>BMJ Open</i> , 2021, 11, e043930.	0.8	9
50	Pro-inflammatory adiponectin in pediatric-onset multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1948-1959.	1.4	9
51	Mendelian randomization provides no evidence for a causal role in the bidirectional relationship between depression and multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 135245852199307.	1.4	11
52	Prioritizing progressive MS rehabilitation research: A call from the International Progressive MS Alliance. <i>Multiple Sclerosis Journal</i> , 2021, 27, 989-1001.	1.4	13
53	Lifetime Prevalence and Comorbidity of Mental Disorders in the Two-wave 2002-2018 Canadian Armed Forces Members and Veterans Mental Health Follow-up Survey (CAFVMHS): Pr�valence et Comorbidit� de Dur�e de vie Des Troubles Mentaux Dans l'Enqu�te de Suivi Sur la Sant� Mentale Aupr�s des Membres des Forces Arm�es Canadiennes et Des ex-Militaires (ESSMFACTM) en Deux Cycles de 2002 � 2018. <i>Canadian Journal of Psychiatry</i> , 2021, 66, 070674372110006.	0.9	15
54	Patterns of Attrition in the Canadian Armed Forces Members and Veterans Mental Health Follow-up Survey (CAFVMHS). <i>Canadian Journal of Psychiatry</i> , 2021, 66, 996-998.	0.9	13

#	ARTICLE	IF	CITATIONS
55	Support for a non-therapist assisted, Internet-based cognitive-behavioral therapy (iCBT) intervention for mental health in rheumatoid arthritis patients. <i>Internet Interventions</i> , 2021, 24, 100385.	1.4	8
56	Uptake and Attitudes About Immunizations in People With Multiple Sclerosis. <i>Neurology: Clinical Practice</i> , 2021, 11, 327-334.	0.8	7
57	Uptake of influenza vaccination among persons with inflammatory bowel disease, multiple sclerosis or rheumatoid arthritis: a population-based matched cohort study. <i>CMAJ Open</i> , 2021, 9, E510-E521.	1.1	10
58	Breast Cancer Survival in Multiple Sclerosis. <i>Neurology</i> , 2021, 97, e13-e22.	1.5	6
59	Psychiatric comorbidity in immune-mediated inflammatory diseases. <i>World Psychiatry</i> , 2021, 20, 298-299.	4.8	14
60	Examining cognitive speed and accuracy dysfunction in youth and young adults with pediatric-onset multiple sclerosis using a computerized neurocognitive battery.. <i>Neuropsychology</i> , 2021, 35, 388-398.	1.0	5
61	The association between childhood maltreatment and pain catastrophizing in individuals with immune-mediated inflammatory diseases. <i>Journal of Psychosomatic Research</i> , 2021, 145, 110479.	1.2	11
62	Comorbidity before and after a diagnosis of inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 637-651.	1.9	25
63	High prevalence of comorbidities at diagnosis in immigrants with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1902-1913.	1.4	6
64	Characterizing Long-term Disability Progression and Employment in NARCOMS Registry Participants with Multiple Sclerosis Taking Dimethyl Fumarate. <i>International Journal of MS Care</i> , 2021, 23, 239-244.	0.4	3
65	Validating the diagnosis of multiple sclerosis using Swedish administrative data in Värmland County. <i>Acta Neurologica Scandinavica</i> , 2021, 144, 680-686.	1.0	4
66	Effect of comorbid mood and anxiety disorders on breast and cervical cancer screening in immune-mediated inflammatory disease. <i>PLoS ONE</i> , 2021, 16, e0249809.	1.1	6
67	The 5-year pre- and post-hospitalization treated prevalence of mental disorders and psychotropic medication use in critically ill patients: a Canadian population-based study. <i>Intensive Care Medicine</i> , 2021, 47, 1450-1461.	3.9	15
68	Higher Framingham Risk Scores are associated with greater loss of brain volume over time in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 54, 103088.	0.9	10
69	Interface of Multiple Sclerosis, Depression, Vascular Disease, and Mortality. <i>Neurology</i> , 2021, 97, e1322-e1333.	1.5	15
70	Prevalence and Risk Factors of Substance Use Disorder in Rheumatoid Arthritis. <i>ACR Open Rheumatology</i> , 2021, 3, 889-896.	0.9	3
71	Colorectal Cancer Survival in Multiple Sclerosis: A Matched Cohort Study. <i>Neurology</i> , 2021, , 10.1212/WNL.00000000000012634.	1.5	6
72	Comorbidity and persistence of disease-modifying therapy use in relapsing remitting multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 56, 103249.	0.9	4

#	ARTICLE	IF	CITATIONS
73	Comparison of Spinal Cord Magnetic Resonance Imaging Features Among Children With Acquired Demyelinating Syndromes. <i>JAMA Network Open</i> , 2021, 4, e2128871.	2.8	27
74	The Canadian prospective cohort study to understand progression in multiple sclerosis (CanProCo): rationale, aims, and study design. <i>BMC Neurology</i> , 2021, 21, 418.	0.8	5
75	Development and Internal Validation of a Disability Algorithm for Multiple Sclerosis in Administrative Data. <i>Frontiers in Neurology</i> , 2021, 12, 754144.	1.1	5
76	Disrupted cognitive development following pediatric acquired demyelinating syndromes: a longitudinal study. <i>Child Neuropsychology</i> , 2021, , 1-22.	0.8	0
77	Disease-Modifying Drug Uptake and Health Service Use in the Ageing MS Population. <i>Frontiers in Immunology</i> , 2021, 12, 794075.	2.2	4
78	Women's Health in Multiple Sclerosis: A Scoping Review. <i>Frontiers in Neurology</i> , 2021, 12, 812147.	1.1	8
79	NARCOMS and Other Registries in Multiple Sclerosis. <i>International Journal of MS Care</i> , 2021, 23, 276-284.	0.4	12
80	Guest Editorial. <i>International Journal of MS Care</i> , 2021, 23, iva-iv.	0.4	0
81	A Survey of Cannabis Use in a Large US-Based Cohort of People with Multiple Sclerosis. <i>International Journal of MS Care</i> , 2021, 23, 245-252.	0.4	1
82	Comparing the MSIS-29 and the Health Utilities Index Mark III in Multiple Sclerosis. <i>Frontiers in Neurology</i> , 2021, 12, 747853.	1.1	0
83	The gut microbiota in pediatric multiple sclerosis and demyelinating syndromes. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 2252-2269.	1.7	34
84	Measures of general and abdominal obesity and disability severity in a large population of people with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2020, 26, 976-986.	1.4	28
85	Validity and Reliability of Screening Measures for Depression and Anxiety Disorders in Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2020, 72, 1130-1139.	1.5	63
86	Developing a crosswalk between the RAND-12 and the health utilities index for multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1102-1110.	1.4	5
87	Serial Anti-Myelin Oligodendrocyte Glycoprotein Antibody Analyses and Outcomes in Children With Demyelinating Syndromes. <i>JAMA Neurology</i> , 2020, 77, 82.	4.5	213
88	Disparities in management and outcomes of myocardial infarction in multiple sclerosis: A matched cohort study. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1560-1568.	1.4	8
89	Factors associated with health care utilization in pediatric multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 38, 101511.	0.9	7
90	Gender identity and sexual orientation affect health care satisfaction, but not utilization, in persons with Multiple Sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 37, 101440.	0.9	8

#	ARTICLE	IF	CITATIONS
91	Social phobia in immune-mediated inflammatory diseases. <i>Journal of Psychosomatic Research</i> , 2020, 128, 109890.	1.2	6
92	Leveraging real-world data to investigate multiple sclerosis disease behavior, prognosis, and treatment. <i>Multiple Sclerosis Journal</i> , 2020, 26, 23-37.	1.4	55
93	Does age at diagnosis influence the use of health services for multiple sclerosis?. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 46, 102555.	0.9	2
94	The 5-Year Incidence of Mental Disorders in a Population-Based ICU Survivor Cohort. <i>Critical Care Medicine</i> , 2020, 48, e675-e683.	0.4	18
95	The Impact of Psychiatric Comorbidity on Health Care Utilization in Inflammatory Bowel Disease: A Population-based Study. <i>Inflammatory Bowel Diseases</i> , 2020, 27, 1462-1474.	0.9	10
96	Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1816-1821.	1.4	965
97	Health service utilization in immigrants with multiple sclerosis. <i>PLoS ONE</i> , 2020, 15, e0234876.	1.1	6
98	Spatial normalization of multiple sclerosis brain MRI data depends on analysis method and software package. <i>Magnetic Resonance Imaging</i> , 2020, 68, 83-94.	1.0	12
99	Evaluating the Risk of Macrovascular Events and Mortality Among People With Multiple Sclerosis in England. <i>JAMA Neurology</i> , 2020, 77, 820.	4.5	55
100	Comorbidity is associated with disease activity in MS. <i>Neurology</i> , 2020, 95, e446-e456.	1.5	33
101	A systematic review of morbidities suggestive of the multiple sclerosis prodrome. <i>Expert Review of Neurotherapeutics</i> , 2020, 20, 799-819.	1.4	26
102	Increased mental health care use by mothers of children with multiple sclerosis. <i>Neurology</i> , 2020, 94, e1040-e1050.	1.5	10
103	Risk of Mortality in Immigrants with Multiple Sclerosis in Ontario, Canada. <i>Neuroepidemiology</i> , 2020, 54, 148-156.	1.1	9
104	Patient Health Questionnaire-9 scores do not accurately estimate depression prevalence: individual participant data meta-analysis. <i>Journal of Clinical Epidemiology</i> , 2020, 122, 115-128.e1.	2.4	113
105	Management of diabetes and hypertension in people with multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 40, 101987.	0.9	13
106	Incidence and temporal trends of co-occurring personality disorder diagnoses in immune-mediated inflammatory diseases. <i>Epidemiology and Psychiatric Sciences</i> , 2020, 29, e84.	1.8	4
107	Interrogation of the Multiple Sclerosis Prodrome Using High-Dimensional Health Data. <i>Neuroepidemiology</i> , 2020, 54, 140-147.	1.1	9
108	Incidence of Adverse Psychiatric Events During Treatment of Inflammatory Bowel Disease With Biologic Therapies: A Systematic Review. <i>Crohn's &amp; Colitis 360</i> , 2020, 2, otz053.	0.5	8

#	ARTICLE	IF	CITATIONS
109	Feasibility of Using a Nationally Representative Telephone Survey to Monitor Multiple Sclerosis Prevalence in the United States. <i>Neuroepidemiology</i> , 2020, 54, 123-130.	1.1	4
110	Predictors of hospitalization in a Canadian MS population: A matched cohort study. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 41, 102028.	0.9	4
111	Development and internal validation of a multimorbidity index that predicts healthcare utilisation using the Canadian Longitudinal Study on Aging. <i>BMJ Open</i> , 2020, 10, e033974.	0.8	5
112	Performance of Regression-Based Norms for Cognitive Functioning of Persons With Multiple Sclerosis in an Independent Sample. <i>Frontiers in Neurology</i> , 2020, 11, 621010.	1.1	9
113	Machine-learning models for depression and anxiety in individuals with immune-mediated inflammatory disease. <i>Journal of Psychosomatic Research</i> , 2020, 134, 110126.	1.2	20
114	Impact of comorbidity on hospitalizations in individuals newly diagnosed with multiple sclerosis: A longitudinal population-based study. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 40, 101955.	0.9	8
115	Disease-modifying therapies as cognition-modifying therapies? Treating cognitive impairment in MS. <i>Neurology</i> , 2020, 94, 957-958.	1.5	5
116	Social Determinants of Outcomes in Inflammatory Bowel Disease. <i>American Journal of Gastroenterology</i> , 2020, 115, 2036-2046.	0.2	24
117	Accuracy of Administrative Hospital Data to Identify Use of Life Support Modalities. A Canadian Study. <i>Annals of the American Thoracic Society</i> , 2020, 17, 229-235.	1.5	7
118	Health service utilization in immigrants with multiple sclerosis. , 2020, 15, e0234876.		0
119	Health service utilization in immigrants with multiple sclerosis. , 2020, 15, e0234876.		0
120	Health service utilization in immigrants with multiple sclerosis. , 2020, 15, e0234876.		0
121	Health service utilization in immigrants with multiple sclerosis. , 2020, 15, e0234876.		0
122	Detection and clinical correlation of leukocortical lesions in pediatric-onset multiple sclerosis on multi-contrast MRI. <i>Multiple Sclerosis Journal</i> , 2019, 25, 980-986.	1.4	11
123	Five years before multiple sclerosis onset: Phenotyping the prodrome. <i>Multiple Sclerosis Journal</i> , 2019, 25, 1092-1101.	1.4	66
124	Increased Burden of Psychiatric Disorders in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 360-368.	0.9	166
125	Higher health care use before a clinically isolated syndrome with or without subsequent MS. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 35, 42-49.	0.9	5
126	Harnessing real-world data to inform treatment decisions in multiple sclerosis. <i>Neurology</i> , 2019, 93, 285-286.	1.5	3



#	ARTICLE	IF	CITATIONS
127	Mounting evidence for a multiple sclerosis prodrome. <i>Nature Reviews Neurology</i> , 2019, 15, 689-690.	4.9	5
128	Early neuroaxonal injury is seen in the acute phase of pediatric optic neuritis. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 36, 101387.	0.9	4
129	Accuracy of FRAX <sup>®</sup> in People With Multiple Sclerosis. <i>Journal of Bone and Mineral Research</i> , 2019, 34, 1095-1100.	3.1	26
130	Validation of the SymptoMScreen with performance-based or clinician-assessed outcomes. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 29, 86-93.	0.9	18
131	Prodrome in relapsing&#x2013;remitting and primary progressive multiple sclerosis. <i>European Journal of Neurology</i> , 2019, 26, 1032-1036.	1.7	23
132	Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders. <i>Lancet Neurology</i> , The, 2019, 18, 185-197.	4.9	110
133	Adjusting for differential misclassification in matched case&#x2013;control studies utilizing health administrative data. <i>Statistics in Medicine</i> , 2019, 38, 3669-3681.	0.8	3
134	Persistence of use of prescribed cannabinoid medicines in Manitoba, Canada: a population&#x2013;based cohort study. <i>Addiction</i> , 2019, 114, 1791-1799.	1.7	14
135	Recognizing the diversity gap in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2019, 25, 1425-1426.	1.4	0
136	High rates of health care utilization in pediatric multiple sclerosis: A Canadian population-based study. <i>PLoS ONE</i> , 2019, 14, e0218215.	1.1	15
137	The association of fatigue and social participation in multiple sclerosis as assessed using two different instruments. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 31, 165-172.	0.9	29
138	Gender differences in information needs and preferences regarding depression among individuals with multiple sclerosis, inflammatory bowel disease and rheumatoid arthritis. <i>Patient Education and Counseling</i> , 2019, 102, 1722-1729.	1.0	12
139	The Prevalence and Risk Factors of Undiagnosed Depression and Anxiety Disorders Among Patients With Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 1674-1680.	0.9	73
140	Traditional risk factors may not explain increased incidence of myocardial infarction in MS. <i>Neurology</i> , 2019, 92, e1624-e1633.	1.5	23
141	Ten-year trajectories of health care utilization by Manitobans with MS predict nursing home entry. <i>Neurology: Clinical Practice</i> , 2019, 9, 16-23.	0.8	1
142	A surface&#x2013;in gradient of thalamic damage evolves in pediatric multiple sclerosis. <i>Annals of Neurology</i> , 2019, 85, 340-351.	2.8	42
143	The prevalence of MS in the United States. <i>Neurology</i> , 2019, 92, e1029-e1040.	1.5	765
144	Validation of an algorithm for identifying MS cases in administrative health claims datasets. <i>Neurology</i> , 2019, 92, e1016-e1028.	1.5	69

#	ARTICLE	IF	CITATIONS
145	A new way to estimate neurologic disease prevalence in the United States. <i>Neurology</i> , 2019, 92, 469-480.	1.5	40
146	Abnormal effector and regulatory T cell subsets in paediatric-onset multiple sclerosis. <i>Brain</i> , 2019, 142, 617-632.	3.7	72
147	Association between disease-modifying therapies for multiple sclerosis and healthcare utilisation on a population level: a retrospective cohort study. <i>BMJ Open</i> , 2019, 9, e033599.	0.8	5
148	MS risk in immigrants in the McDonald era. <i>Neurology</i> , 2019, 93, e2203-e2215.	1.5	17
149	Identifying people with multiple sclerosis in the Canadian Primary Care Sentinel Surveillance Network. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2019, 5, 205521731989436.	0.5	2
150	Author response: Comorbid anxiety, depression, and cognition in MS and other immune-mediated disorders. <i>Neurology</i> , 2019, 93, 1081-1082.	1.5	2
151	Functional gastrointestinal disorders negatively affect health-related quality of life in MS. <i>Neurology: Clinical Practice</i> , 2019, 9, 381-390.	0.8	7
152	Multiple sclerosis is associated with low bone mineral density and osteoporosis. <i>Neurology: Clinical Practice</i> , 2019, 9, 391-399.	0.8	20
153	Pediatric-onset multiple sclerosis is associated with reduced parental health-related quality of life and family functioning. <i>Multiple Sclerosis Journal</i> , 2019, 25, 1661-1672.	1.4	21
154	MRI utilization during the diagnostic and post-diagnostic phases in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 28, 138-144.	0.9	4
155	Persistence and adherence to the new oral disease-modifying therapies for multiple sclerosis: A population-based study. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 27, 364-369.	0.9	20
156	Factors associated with receiving bone mineral density screening among people with multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 28, 305-308.	0.9	9
157	Comorbid anxiety, depression, and cognition in MS and other immune-mediated disorders. <i>Neurology</i> , 2019, 92, .	1.5	79
158	Diabetes and anxiety adversely affect cognition in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 27, 164-170.	0.9	33
159	International consensus on quality standards for brain health-focused care in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2019, 25, 1809-1818.	1.4	55
160	Use of eHealth and mHealth technology by persons with multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 27, 13-19.	0.9	58
161	Rising incidence of psychiatric disorders before diagnosis of immune-mediated inflammatory disease. <i>Epidemiology and Psychiatric Sciences</i> , 2019, 28, 333-342.	1.8	91
162	The contribution of secondhand tobacco smoke exposure to pediatric multiple sclerosis risk. <i>Multiple Sclerosis Journal</i> , 2019, 25, 515-522.	1.4	32

#	ARTICLE	IF	CITATIONS
163	Comorbidity in multiple sclerosis: Past, present and future. <i>Clinical and Investigative Medicine</i> , 2019, 42, E5-E12.	0.3	28
164	National estimates of self-reported sitting time in adults with multiple sclerosis. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2018, 4, 205521731875436.	0.5	22
165	A survey of dietary characteristics in a large population of people with multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 22, 12-18.	0.9	46
166	Comprehensive systematic review summary: Disease-modifying therapies for adults with multiple sclerosis. <i>Neurology</i> , 2018, 90, 789-800.	1.5	107
167	Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis. <i>Neurology</i> , 2018, 90, 777-788.	1.5	406
168	Disease-modifying therapy in multiple sclerosis: Two guidelines (almost) passing in the night. <i>Multiple Sclerosis Journal</i> , 2018, 24, 558-562.	1.4	5
169	The Validity and Reliability of Screening Measures for Depression and Anxiety Disorders in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 1867-1875.	0.9	84
170	Factors associated with excessive sitting time in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 21, 71-77.	0.9	9
171	Maternal and fetal risks of natalizumab exposure in utero. <i>Neurology</i> , 2018, 90, 443-444.	1.5	2
172	MRI and laboratory features and the performance of international criteria in the diagnosis of multiple sclerosis in children and adolescents: a prospective cohort study. <i>The Lancet Child and Adolescent Health</i> , 2018, 2, 191-204.	2.7	86
173	Increased Burden of Psychiatric Disorders in Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2018, 70, 970-978.	1.5	100
174	Physical comorbidities increase the risk of psychiatric comorbidity in immune-mediated inflammatory disease. <i>General Hospital Psychiatry</i> , 2018, 51, 71-78.	1.2	19
175	The validity and reliability of screening measures for depression and anxiety disorders in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 20, 9-15.	0.9	113
176	Treatment satisfaction and bothersome bladder, bowel, sexual symptoms in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 20, 16-21.	0.9	28
177	Serum neurofilament light chain in relapsing-remitting MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2018, 5, e421.	3.1	2
178	Clinical Profile of Persons with Multiple Sclerosis Across the Continuum of Care. <i>Canadian Journal of Neurological Sciences</i> , 2018, 45, 188-198.	0.3	10
179	Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. <i>Lancet Neurology</i> , The, 2018, 17, 162-173.	4.9	4,605
180	Can $T_1$ -w/ $T_2$ -w ratio be used as a myelin-specific measure in subcortical structures? Comparisons between FSE-based $T_1$ -w/ $T_2$ -w ratios, GRASE-based $T_1$ -w/ $T_2$ -w ratios and multi-echo GRASE-based myelin water fractions. <i>NMR in Biomedicine</i> , 2018, 31, e3868.	1.6	66

#	ARTICLE	IF	CITATIONS
181	Effects of physical comorbidities on disability progression in multiple sclerosis. <i>Neurology</i> , 2018, 90, e419-e427.	1.5	67
182	Disease-modifying drugs for multiple sclerosis and infection risk: a cohort study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 1050-1056.	0.9	80
183	Validation of the PHQ-9 for Suicidal Ideation in Persons with Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 1641-1648.	0.9	21
184	Lower prevalence of multiple sclerosis in First Nations Canadians. <i>Neurology: Clinical Practice</i> , 2018, 8, 33-39.	0.8	6
185	Establishing the Incidence and Prevalence of Multiple Sclerosis in Saskatchewan. <i>Canadian Journal of Neurological Sciences</i> , 2018, 45, 295-303.	0.3	48
186	Temporal trends in multiple sclerosis prevalence and incidence in a large population. <i>Neurology</i> , 2018, 90, e1435-e1441.	1.5	60
187	Psychiatric comorbidity is associated with disability progression in multiple sclerosis. <i>Neurology</i> , 2018, 90, e1316-e1323.	1.5	136
188	A contemporary profile of primary progressive multiple sclerosis participants from the NARCOMS Registry. <i>Multiple Sclerosis Journal</i> , 2018, 24, 951-962.	1.4	11
189	Validation of an algorithm to detect severe MS relapses in administrative health databases. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 19, 134-139.	0.9	6
190	Diet quality is associated with disability and symptom severity in multiple sclerosis. <i>Neurology</i> , 2018, 90, e1-e11.	1.5	149
191	Pharmaceutical cannabinoid use in Manitoba, 2004/05 to 2014/15: a population-based cross-sectional study. <i>CMAJ Open</i> , 2018, 6, E637-E642.	1.1	1
192	Diagnoses of Depression and Anxiety Versus Current Symptoms and Quality of Life in Multiple Sclerosis. <i>International Journal of MS Care</i> , 2018, 20, 76-84.	0.4	35
193	Obesity and brain volume loss in multiple sclerosis. <i>Neurology</i> , 2018, 91, 1079-1080.	1.5	1
194	Incidence and prevalence of MS in children. <i>Neurology</i> , 2018, 91, e1579-e1590.	1.5	26
195	Pseudobulbar affect. <i>Neurology: Clinical Practice</i> , 2018, 8, 472-481.	0.8	10
196	Physical activity and dentate gyrus volume in pediatric acquired demyelinating syndromes. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2018, 5, e499.	3.1	4
197	Adverse psychiatric effects of disease-modifying therapies in multiple Sclerosis: A systematic review. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 26, 124-156.	0.9	33
198	Comorbidities Are Associated with Altered Health Services Use in Multiple Sclerosis: A Prospective Cohort Study. <i>Neuroepidemiology</i> , 2018, 51, 1-10.	1.1	18

#	ARTICLE	IF	CITATIONS
199	Psychiatric comorbidity increases mortality in immune-mediated inflammatory diseases. <i>General Hospital Psychiatry</i> , 2018, 53, 65-72.	1.2	73
200	Factors associated with perceived need for mental health care in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 25, 179-185.	0.9	14
201	Use of the new oral disease-modifying therapies for multiple sclerosis in British Columbia, Canada: the first five-years. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 25, 57-60.	0.9	8
202	Common variation near IRF6 is associated with IFN- $\gamma$ -induced liver injury in multiple sclerosis. <i>Nature Genetics</i> , 2018, 50, 1081-1085.	9.4	32
203	Contesting Medical Miracles: A Collective Action Framing Analysis of CCSVI and Venous Angioplasty (â€œLiberation Therapyâ€) for People With Multiple Sclerosis in News and Social Media. <i>Science Communication</i> , 2018, 40, 469-498.	1.8	1
204	Identifying priority outcomes that influence selection of disease-modifying therapies in MS. <i>Neurology: Clinical Practice</i> , 2018, 8, 179-185.	0.8	23
205	Mining healthcare data for markers of the multiple sclerosis prodrome. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 25, 232-240.	0.9	18
206	Identifying optic neuritis and transverse myelitis using administrative data. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 25, 258-264.	0.9	6
207	Registry Cohort Study to Determine Risk for Multiple Sclerosis after Vaccination for Pandemic Influenza A(H1N1) with Arepanrix, Manitoba, Canada. <i>Emerging Infectious Diseases</i> , 2018, 24, 1267-1274.	2.0	13
208	The association of fatigue, pain, depression and anxiety with work and activity impairment in immune mediated inflammatory diseases. <i>PLoS ONE</i> , 2018, 13, e0198975.	1.1	58
209	Effects of Psychiatric Comorbidity in Immune-Mediated Inflammatory Disease: Protocol for a Prospective Study. <i>JMIR Research Protocols</i> , 2018, 7, e15.	0.5	38
210	The Standards of Reporting of Neurological Disorders (STROND) checklist: Application to multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2017, 23, 23-33.	1.4	2
211	Upper limb impairment is associated with use of assistive devices and unemployment in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2017, 13, 87-92.	0.9	23
212	Increased incidence and prevalence of psoriasis in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2017, 13, 81-86.	0.9	28
213	Infection-related health care utilization among people with and without multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1506-1516.	1.4	76
214	Smokers with MS have greater decrements in quality of life and disability than non-smokers. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1772-1781.	1.4	20
215	Potentially Modifiable Factors Associated With Physical Activity in Individuals With Multiple Sclerosis. <i>Research in Nursing and Health</i> , 2017, 40, 143-152.	0.8	10
216	Health-care use before a first demyelinating event suggestive of a multiple sclerosis prodrome: a matched cohort study. <i>Lancet Neurology</i> , The, 2017, 16, 445-451.	4.9	105

#	ARTICLE	IF	CITATIONS
217	Evaluating the safety of $\beta^2$ -interferons in MS. <i>Neurology</i> , 2017, 88, 2310-2320.	1.5	45
218	A gestational dose of vitamin D per day keeps the MS doctor away. <i>Neurology</i> , 2017, 88, 13-14.	1.5	4
219	Hospitalization is associated with subsequent disability in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2017, 14, 23-28.	0.9	7
220	Markedly increased incidence of critical illness in adults with Type 1 diabetes. <i>Diabetic Medicine</i> , 2017, 34, 1414-1420.	1.2	4
221	Application of pharmacogenomics to investigate adverse drug reactions to the disease-modifying treatments for multiple sclerosis: a case-control study protocol for dimethyl fumarate-induced lymphopenia. <i>BMJ Open</i> , 2017, 7, e016276.	0.8	2
222	Increased Incidence of Critical Illness in Psoriasis. <i>Journal of Cutaneous Medicine and Surgery</i> , 2017, 21, 395-400.	0.6	1
223	The computer-based Symbol Digit Modalities Test: establishing age-expected performance in healthy controls and evaluation of pediatric MS patients. <i>Neurological Sciences</i> , 2017, 38, 635-642.	0.9	14
224	Systematic Review and Meta-analysis of Interventions for Depression and Anxiety in Persons With Rheumatoid Arthritis. <i>Journal of Clinical Rheumatology</i> , 2017, 23, 425-434.	0.5	75
225	White matter changes in paediatric multiple sclerosis and monophasic demyelinating disorders. <i>Brain</i> , 2017, 140, 1300-1315.	3.7	52
226	Adherence to disease-modifying therapies for multiple sclerosis and subsequent hospitalizations. <i>Pharmacoepidemiology and Drug Safety</i> , 2017, 26, 702-711.	0.9	27
227	Monophasic demyelination reduces brain growth in children. <i>Neurology</i> , 2017, 88, 1744-1750.	1.5	43
228	What is the risk of suicide in multiple sclerosis?. <i>Multiple Sclerosis Journal</i> , 2017, 23, 755-756.	1.4	5
229	High hypothetical interest in physician-assisted death in multiple sclerosis. <i>Neurology</i> , 2017, 88, 1528-1534.	1.5	25
230	Comorbidity in multiple sclerosis: implications for patient care. <i>Nature Reviews Neurology</i> , 2017, 13, 375-382.	4.9	161
231	Employment and absenteeism in working-age persons with multiple sclerosis. <i>Journal of Medical Economics</i> , 2017, 20, 493-502.	1.0	55
232	Effect of adherence to the first-generation injectable immunomodulatory drugs on disability accumulation in multiple sclerosis: a longitudinal cohort study. <i>BMJ Open</i> , 2017, 7, e018612.	0.8	4
233	Increased relapse rate during pregnancy and postpartum in neuromyelitis optica. <i>Neurology</i> , 2017, 89, 2220-2221.	1.5	4
234	Author response: High hypothetical interest in physician-assisted death in multiple sclerosis. <i>Neurology</i> , 2017, 89, 1429-1430.	1.5	0

#	ARTICLE	IF	CITATIONS
235	Preventing multiple sclerosis. <i>Neurology</i> , 2017, 89, 1538-1539.	1.5	5
236	Increased incidence of psychiatric disorders in immune-mediated inflammatory disease. <i>Journal of Psychosomatic Research</i> , 2017, 101, 17-23.	1.2	131
237	Disease-Modifying Therapies and Adherence in Multiple Sclerosis: Comparing Patient Self-Report with Pharmacy Records. <i>Neuroepidemiology</i> , 2017, 48, 124-130.	1.1	6
238	Perspectives on marijuana use and effectiveness. <i>Neurology: Clinical Practice</i> , 2017, 7, 333-343.	0.8	24
239	Comorbidity increases the risk of relapse in multiple sclerosis. <i>Neurology</i> , 2017, 89, 2455-2461.	1.5	77
240	Depression in multiple sclerosis. <i>International Review of Psychiatry</i> , 2017, 29, 463-472.	1.4	146
241	Determinants of non-adherence to disease-modifying therapies in multiple sclerosis: A cross-Canada prospective study. <i>Multiple Sclerosis Journal</i> , 2017, 23, 588-596.	1.4	44
242	Cell-based therapeutic strategies for multiple sclerosis. <i>Brain</i> , 2017, 140, 2776-2796.	3.7	139
243	Estimating annual prevalence of depression and anxiety disorder in multiple sclerosis using administrative data. <i>BMC Research Notes</i> , 2017, 10, 619.	0.6	38
244	Trigeminal Neuralgia Commonly Precedes the Diagnosis of Multiple Sclerosis. <i>International Journal of MS Care</i> , 2017, 19, 240-246.	0.4	32
245	Caught in a no-win situation: discussions about CCSVI between persons with multiple sclerosis and their neurologists – a qualitative study. <i>BMC Neurology</i> , 2017, 17, 176.	0.8	8
246	Discriminative ability of quality of life measures in multiple sclerosis. <i>Health and Quality of Life Outcomes</i> , 2017, 15, 246.	1.0	11
247	Persistence to disease-modifying therapies for multiple sclerosis in a Canadian cohort. <i>Patient Preference and Adherence</i> , 2017, Volume 11, 1093-1101.	0.8	14
248	Multiple sclerosis in Canada 2011 to 2031: results of a microsimulation modelling study of epidemiological and economic impacts. <i>Health Promotion and Chronic Disease Prevention in Canada: Research, Policy and Practice</i> , 2017, 37, 37-48.	0.8	57
249	Reproductive Issues in Multiple Sclerosis: Parental MS and Child Outcomes (The Research Perspective). , 2017, , 63-72.		0
250	Health care utilisation before and after intensive care unit admission in rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 975-982.	0.4	2
251	Multiple sclerosis in First Nations Canadians: A pilot comparison study. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2016, 2, 205521731666609.	0.5	1
252	Comorbidity in Multiple Sclerosis. <i>International Journal of MS Care</i> , 2016, 18, 271-272.	0.4	15



#	ARTICLE	IF	CITATIONS
253	Systematic review of interventions for depression and anxiety in persons with inflammatory bowel disease. <i>BMC Research Notes</i> , 2016, 9, 404.	0.6	40
254	A population-based study comparing multiple sclerosis clinic users and non-users in British Columbia, Canada. <i>European Journal of Neurology</i> , 2016, 23, 1093-1100.	1.7	29
255	Declines in the diagnosis of primary progressive MS: A critical change in phenotype or critical measurement error?. <i>Multiple Sclerosis Journal</i> , 2016, 22, 983-985.	1.4	2
256	Medical Tourism for CCSVI Procedures in People with Multiple Sclerosis: An Observational Study. <i>Canadian Journal of Neurological Sciences</i> , 2016, 43, 360-367.	0.3	9
257	Adherence and persistence to drug therapies for multiple sclerosis: A population-based study. <i>Multiple Sclerosis and Related Disorders</i> , 2016, 8, 78-85.	0.9	53
258	Chronic lung disease and multiple sclerosis: Incidence, prevalence, and temporal trends. <i>Multiple Sclerosis and Related Disorders</i> , 2016, 8, 86-92.	0.9	14
259	Differing trends in the incidence of vascular comorbidity in MS and the general population. <i>Neurology: Clinical Practice</i> , 2016, 6, 120-128.	0.8	42
260	A Cross-Sectional Study of the Impact of Spasticity on Daily Activities in Multiple Sclerosis. <i>Patient</i> , 2016, 9, 537-546.	1.1	45
261	Physical comorbidities increase the risk of psychiatric comorbidity in multiple sclerosis. <i>Brain and Behavior</i> , 2016, 6, e00493.	1.0	24
262	Incidence of Mood or Anxiety Disorders in Children of Parents with Multiple Sclerosis. <i>Paediatric and Perinatal Epidemiology</i> , 2016, 30, 356-366.	0.8	15
263	Care of persons with MS in clinical practice. <i>Neurology: Clinical Practice</i> , 2016, 6, 288-290.	0.8	0
264	Performance of administrative case definitions for depression and anxiety in inflammatory bowel disease. <i>Journal of Psychosomatic Research</i> , 2016, 89, 107-113.	1.2	50
265	Health insurance affects the use of disease-modifying therapy in multiple sclerosis. <i>Neurology</i> , 2016, 87, 365-374.	1.5	31
266	Examining the joint effect of disability, health behaviors, and comorbidity on mortality in MS. <i>Neurology: Clinical Practice</i> , 2016, 6, 397-408.	0.8	18
267	Children of chronically ill parents: Relationship between parental multiple sclerosis and childhood developmental health. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1452-1462.	1.4	24
268	Differing trends in the incidence of vascular comorbidity in MS and the general population. <i>Neurology: Clinical Practice</i> , 2016, 6, 201-202.	0.8	0
269	A Population-based Study of Intensive Care Unit Admissions in Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2016, 43, 26-33.	1.0	26
270	The challenge of comorbidity in clinical trials for multiple sclerosis. <i>Neurology</i> , 2016, 86, 1437-1445.	1.5	48



#	ARTICLE	IF	CITATIONS
271	Recommendations for observational studies of comorbidity in multiple sclerosis. <i>Neurology</i> , 2016, 86, 1446-1453.	1.5	64
272	Examining the effects of comorbidities on disease-modifying therapy use in multiple sclerosis. <i>Neurology</i> , 2016, 86, 1287-1295.	1.5	79
273	Peripartum depression in parents with multiple sclerosis and psychiatric disorders in children. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1830-1840.	1.4	16
274	Health-related quality of life in multiple sclerosis. <i>Neurology</i> , 2016, 86, 1417-1424.	1.5	156
275	Sex differences in comorbidity at diagnosis of multiple sclerosis. <i>Neurology</i> , 2016, 86, 1279-1286.	1.5	86
276	Heavy metals, organic solvents, and multiple sclerosis: An exploratory look at gene-environment interactions. <i>Archives of Environmental and Occupational Health</i> , 2016, 71, 26-34.	0.7	30
277	Systematic review and meta-analysis of interventions for depression and anxiety in persons with multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2016, 5, 12-26.	0.9	133
278	Adverse health behaviours are associated with depression and anxiety in multiple sclerosis: A prospective multisite study. <i>Multiple Sclerosis Journal</i> , 2016, 22, 685-693.	1.4	27
279	Five-minute Apgar score as a marker for developmental vulnerability at 5 years of age. <i>Archives of Disease in Childhood: Fetal and Neonatal Edition</i> , 2016, 101, F114-F120.	1.4	42
280	Examining the Relationship Between Family Caregivers' Emotional States and Ability to Empathize with Patients with Multiple Sclerosis. <i>International Journal of MS Care</i> , 2016, 18, 122-128.	0.4	10
281	Fatigue and Comorbidities in Multiple Sclerosis. <i>International Journal of MS Care</i> , 2016, 18, 96-104.	0.4	38
282	Screening Tools for Anxiety in People with Multiple Sclerosis. <i>International Journal of MS Care</i> , 2016, 18, 273-281.	0.4	24
283	Antidepressant Drug Treatment in Association with Multiple Sclerosis Disease-Modifying Therapy. <i>International Journal of MS Care</i> , 2016, 18, 305-310.	0.4	26
284	Predictors of ICU Admission and Outcomes 1 Year Post-Admission in Persons with IBD. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 1.	0.9	4
285	Predictors of chronic cerebrospinal venous insufficiency procedure use among older people with multiple sclerosis: a national case-control study. <i>BMC Health Services Research</i> , 2015, 15, 161.	0.9	1
286	Effect of comorbidity on mortality in multiple sclerosis. <i>Neurology</i> , 2015, 85, 240-247.	1.5	163
287	Impact of parental multiple sclerosis on early childhood development: A retrospective cohort study. <i>Multiple Sclerosis Journal</i> , 2015, 21, 1172-1183.	1.4	15
288	Impact of multiple sclerosis relapse: The NARCOMS participant perspective. <i>Multiple Sclerosis and Related Disorders</i> , 2015, 4, 234-240.	0.9	45

#	ARTICLE	IF	CITATIONS
289	Health care utilization before and after intensive care unit admission in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2015, 4, 296-303.	0.9	10
290	A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: Overview. <i>Multiple Sclerosis Journal</i> , 2015, 21, 263-281.	1.4	273
291	The incidence and prevalence of psychiatric disorders in multiple sclerosis: A systematic review. <i>Multiple Sclerosis Journal</i> , 2015, 21, 305-317.	1.4	381
292	Predictors of Fear of Sexual Rejection in Individuals with Multiple Sclerosis. <i>Sexuality and Disability</i> , 2015, 33, 53-61.	0.4	3
293	A Practical, Global Perspective on Using Administrative Data to Conduct Intensive Care Unit Research. <i>Annals of the American Thoracic Society</i> , 2015, 12, 1373-1386.	1.5	25
294	Causes of death among persons with multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2015, 4, 484-490.	0.9	31
295	High incidence and increasing prevalence of multiple sclerosis in British Columbia, Canada: findings from over two decades (1991–2010). <i>Journal of Neurology</i> , 2015, 262, 2352-2363.	1.8	100
296	Recovery From Central Nervous System Acute Demyelination in Children. <i>Pediatrics</i> , 2015, 136, e115-e123.	1.0	40
297	Puberty in females enhances the risk of an outcome of multiple sclerosis in children and the development of central nervous system autoimmunity in mice. <i>Multiple Sclerosis Journal</i> , 2015, 21, 735-748.	1.4	47
298	The incidence and prevalence of comorbid gastrointestinal, musculoskeletal, ocular, pulmonary, and renal disorders in multiple sclerosis: A systematic review. <i>Multiple Sclerosis Journal</i> , 2015, 21, 332-341.	1.4	39
299	Comorbidity is associated with pain-related activity limitations in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2015, 4, 470-476.	0.9	40
300	Comorbidity increases the risk of hospitalizations in multiple sclerosis. <i>Neurology</i> , 2015, 84, 350-358.	1.5	77
301	Differences in the burden of psychiatric comorbidity in MS vs the general population. <i>Neurology</i> , 2015, 85, 1972-1979.	1.5	106
302	A systematic review of the incidence and prevalence of autoimmune disease in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2015, 21, 282-293.	1.4	131
303	A systematic review of the incidence and prevalence of cancer in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2015, 21, 294-304.	1.4	79
304	A systematic review of the incidence and prevalence of sleep disorders and seizure disorders in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2015, 21, 342-349.	1.4	100
305	A systematic review of the incidence and prevalence of cardiac, cerebrovascular, and peripheral vascular disease in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2015, 21, 318-331.	1.4	131
306	Predictors of Body Image Related Sexual Dysfunction in Men and Women with Multiple Sclerosis. <i>Sexuality and Disability</i> , 2015, 33, 63-73.	0.4	11

#	ARTICLE	IF	CITATIONS
307	Care Partners and Multiple Sclerosis. <i>International Journal of MS Care</i> , 2015, 17, 253-260.	0.4	26
308	Patient perspectives on switching disease-modifying therapies in the NARCOMS registry. <i>Patient Preference and Adherence</i> , 2014, 8, 971.	0.8	15
309	Psychiatric comorbidity in multiple sclerosis: It's not the genes. <i>Multiple Sclerosis Journal</i> , 2014, 20, 1803-1805.	1.4	5
310	Characteristics associated with drug-induced liver injury from interferon beta in multiple sclerosis patients. <i>Expert Opinion on Drug Safety</i> , 2014, 13, 1305-1317.	1.0	8
311	Reliability of Regression-Based Normative Data for the Oral Symbol Digit Modalities Test: An Evaluation of Demographic Influences, Construct Validity, and Impairment Classification Rates in Multiple Sclerosis Samples. <i>Clinical Neuropsychologist</i> , 2014, 28, 281-299.	1.5	32
312	Dramatically changing rates and reasons for hospitalization in multiple sclerosis. <i>Neurology</i> , 2014, 83, 929-937.	1.5	89
313	The Canadian survey of health, lifestyle and ageing with multiple sclerosis: methodology and initial results. <i>BMJ Open</i> , 2014, 4, e005718-e005718.	0.8	34
314	Intensive care unit admission in multiple sclerosis. <i>Neurology</i> , 2014, 82, 2112-2119.	1.5	45
315	Functional-structural correlations in the afferent visual pathway in pediatric demyelination. <i>Neurology</i> , 2014, 83, 2147-2152.	1.5	37
316	Cerebral arterial and venous blood flow in adolescent multiple sclerosis patients and age-matched controls using phase contrast MRI. <i>Journal of Magnetic Resonance Imaging</i> , 2014, 40, 341-347.	1.9	13
317	Children of chronically ill parents: the silence of research. <i>Child: Care, Health and Development</i> , 2014, 40, 753-754.	0.8	2
318	Administrative databases for observational studies in multiple sclerosis: power or peril?. <i>Multiple Sclerosis Journal</i> , 2014, 20, 1151-1152.	1.4	1
319	The impact of sexual dysfunction on health-related quality of life in people with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2014, 20, 610-616.	1.4	90
320	Intensive care unit admission in multiple sclerosis: Increased incidence and increased mortality. <i>Neurology</i> , 2014, 83, 2192-2193.	1.5	0
321	Antinuclear antibodies in pediatric acquired demyelinating diseases of the central nervous system. <i>Multiple Sclerosis Journal</i> , 2014, 20, 1665-1666.	1.4	0
322	Increased Incidence of Critical Illness Among Patients With Inflammatory Bowel Disease: A Population-Based Study. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 2063-2070.e4.	2.4	12
323	MS incidence and prevalence in Africa, Asia, Australia and New Zealand: A systematic review. <i>Multiple Sclerosis and Related Disorders</i> , 2014, 3, 48-60.	0.9	32
324	Prevalence of neurological conditions across the continuum of care based on interRAI assessments. <i>BMC Health Services Research</i> , 2014, 14, 29.	0.9	16

#	ARTICLE	IF	CITATIONS
325	Obesity and HLA in multiple sclerosis: Weighty matters. <i>Neurology</i> , 2014, 82, 826-827.	1.5	8
326	Children and adolescents adjustment to parental multiple sclerosis: a systematic review. <i>BMC Neurology</i> , 2014, 14, 107.	0.8	25
327	Application of Three Focused Cluster Detection Methods to Study Geographic Variation in the Incidence of Multiple Sclerosis in Manitoba, Canada. <i>Neuroepidemiology</i> , 2014, 43, 38-48.	1.1	14
328	Health Literacy Association With Health Behaviors and Health Care Utilization in Multiple Sclerosis: A Cross-Sectional Study. <i>Interactive Journal of Medical Research</i> , 2014, 3, e3.	0.6	37
329	Performance of administrative case definitions for comorbidity in multiple sclerosis in Manitoba and Nova Scotia. <i>Chronic Diseases and Injuries in Canada</i> , 2014, 34, 145-153.	1.4	17
330	Performance of administrative case definitions for comorbidity in multiple sclerosis in Manitoba and Nova Scotia. <i>Chronic Diseases and Injuries in Canada</i> , 2014, 34, 145-53.	1.4	8
331	Mental comorbidity and multiple sclerosis: validating administrative data to support population-based surveillance. <i>BMC Neurology</i> , 2013, 13, 16.	0.8	122
332	Prevalence and incidence of ischemic heart disease in multiple sclerosis: A population-based validation study. <i>Multiple Sclerosis and Related Disorders</i> , 2013, 2, 355-361.	0.9	34
333	Clinical Features of Dog- and Bat-Acquired Rabies in Humans. <i>Clinical Infectious Diseases</i> , 2013, 57, 689-696.	2.9	42
334	Incidence and prevalence of multiple sclerosis in Europe: a systematic review. <i>BMC Neurology</i> , 2013, 13, 128.	0.8	392
335	The multiple sclerosis relapse experience: patient-reported outcomes from the North American Research Committee on Multiple Sclerosis (NARCOMS) Registry. <i>BMC Neurology</i> , 2013, 13, 119.	0.8	31
336	Incidence and Prevalence of Multiple Sclerosis in the Americas: A Systematic Review. <i>Neuroepidemiology</i> , 2013, 40, 195-210.	1.1	169
337	Substantial burden of dizziness in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2013, 2, 21-28.	0.9	31
338	The prevalence of urinary catheterization in women and men with multiple sclerosis. <i>Journal of Spinal Cord Medicine</i> , 2013, 36, 632-637.	0.7	29
339	The Utility of Administrative Data for Surveillance of Comorbidity in Multiple Sclerosis: A Validation Study. <i>Neuroepidemiology</i> , 2013, 40, 85-92.	1.1	62
340	Clinical and MRI activity as determinants of sample size for pediatric multiple sclerosis trials. <i>Neurology</i> , 2013, 81, 1215-1221.	1.5	31
341	High rates of physician services utilization at least five years before multiple sclerosis diagnosis. <i>Multiple Sclerosis Journal</i> , 2013, 19, 1113-1119.	1.4	46
342	Epstein-Barr virus in oral shedding of children with multiple sclerosis. <i>Neurology</i> , 2013, 81, 1392-1399.	1.5	48

#	ARTICLE	IF	CITATIONS
343	General Health Issues in Multiple Sclerosis. CONTINUUM Lifelong Learning in Neurology, 2013, 19, 1046-1057.	0.4	52
344	Exploring the Implications of Small-Area Variation in the Incidence of Multiple Sclerosis. American Journal of Epidemiology, 2013, 178, 1059-1066.	1.6	15
345	Observational studies of treatment effectiveness: useful, useless or somewhere in between?. Multiple Sclerosis Journal, 2013, 19, 707-708.	1.4	3
346	No Evidence for Impairment of Venous Hemodynamics in Children or Young Adults with Pediatric-Onset Multiple Sclerosis. American Journal of Neuroradiology, 2013, 34, 2366-2372.	1.2	4
347	Masquerades of Acquired Demyelination in Children. Journal of Child Neurology, 2013, 28, 184-197.	0.7	19
348	The Multiple Sclerosis Intimacy and Sexuality Questionnaire "re-validation and development of a 15-item version with a large US sample. Multiple Sclerosis Journal, 2013, 19, 1197-1203.	1.4	71
349	"Seeing" in NARCOMS: a look at vision-related quality of life in the NARCOMS registry. Multiple Sclerosis Journal, 2013, 19, 953-960.	1.4	27
350	Diagnostic data for neurological conditions in interRAI assessments in home care, nursing home and mental health care settings: a validity study. BMC Health Services Research, 2013, 13, 457.	0.9	60
351	The Incidence and Prevalence of Multiple Sclerosis in Nova Scotia, Canada. Canadian Journal of Neurological Sciences, 2013, 40, 824-831.	0.3	53
352	Patient Recruitment by Neurological Registries. Canadian Journal of Neurological Sciences, 2013, 40, S23-S26.	0.3	7
353	Neurological Registry Feasibility and Sustainability. Canadian Journal of Neurological Sciences, 2013, 40, S55-S59.	0.3	3
354	The Incidence and Prevalence of Neuromyelitis Optica. International Journal of MS Care, 2013, 15, 113-118.	0.4	47
355	Interaction of HLA-DRB1*1501 and TNF-Alpha in a Population-based Case-control Study of Multiple Sclerosis. Immunology and Infectious Diseases, 2013, 1, 10-17.	0.1	1
356	Preferred Sources of Health Information in Persons With Multiple Sclerosis: Degree of Trust and Information Sought. Journal of Medical Internet Research, 2013, 15, e67.	2.1	121
357	Change in the Health-Related Quality of Life of Multiple Sclerosis Patients over 5 Years. International Journal of MS Care, 2013, 15, 46-53.	0.4	15
358	Effect of Physical Comorbidities on Risk of Depression in Multiple Sclerosis. International Journal of MS Care, 2013, 15, 34-43.	0.4	0
359	The incidence and prevalence of multiple sclerosis in Nova Scotia, Canada. Canadian Journal of Neurological Sciences, 2013, 40, 824-31.	0.3	20
360	Rising prevalence of vascular comorbidities in multiple sclerosis: validation of administrative definitions for diabetes, hypertension, and hyperlipidemia. Multiple Sclerosis Journal, 2012, 18, 1310-1319.	1.4	109

#	ARTICLE	IF	CITATIONS
361	The Incidence and Prevalence of Thyroid Disease Do Not Differ in the Multiple Sclerosis and General Populations: A Validation Study Using Administrative Data. <i>Neuroepidemiology</i> , 2012, 39, 135-142.	1.1	35
362	Vitamin D in MS. <i>Neurology</i> , 2012, 79, 208-210.	1.5	18
363	2010 McDonald criteria for diagnosing pediatric multiple sclerosis. <i>Annals of Neurology</i> , 2012, 72, 211-223.	2.8	117
364	The incidence and prevalence of fibromyalgia are higher in multiple sclerosis than the general population: A population-based study. <i>Multiple Sclerosis and Related Disorders</i> , 2012, 1, 162-167.	0.9	24
365	Cumulative impact of comorbidity on quality of life in MS. <i>Acta Neurologica Scandinavica</i> , 2012, 125, 180-186.	1.0	68
366	Design, methodological issues and participation in a multiple sclerosis case-control study. <i>Acta Neurologica Scandinavica</i> , 2012, 126, 197-204.	1.0	5
367	Demographic, Genetic, and Environmental Factors That Modify Disease Course. <i>Neurologic Clinics</i> , 2011, 29, 323-341.	0.8	7
368	Validation of the NARCOMS Registry. <i>International Journal of MS Care</i> , 2011, 13, 114-120.	0.4	19
369	Association between comorbidity and clinical characteristics of MS. <i>Acta Neurologica Scandinavica</i> , 2011, 124, 135-141.	1.0	67
370	Clinical, environmental, and genetic determinants of multiple sclerosis in children with acute demyelination: a prospective national cohort study. <i>Lancet Neurology</i> , The, 2011, 10, 436-445.	4.9	267
371	MRI parameters for prediction of multiple sclerosis diagnosis in children with acute CNS demyelination: a prospective national cohort study. <i>Lancet Neurology</i> , The, 2011, 10, 1065-1073.	4.9	159
372	Substantial adverse association of visual and vascular comorbidities on visual disability in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2011, 17, 1464-1471.	1.4	38
373	Smokers with Multiple Sclerosis Are More Likely to Report Comorbid Autoimmune Diseases. <i>Neuroepidemiology</i> , 2011, 36, 85-90.	1.1	18
374	Emerging effects of comorbidities on multiple sclerosis. <i>Lancet Neurology</i> , The, 2010, 9, 820-828.	4.9	156
375	Cognitive test results in pediatric MS. <i>Neurology</i> , 2010, 75, 2054-2055.	1.5	2
376	Vascular comorbidity is associated with more rapid disability progression in multiple sclerosis. <i>Neurology</i> , 2010, 74, 1041-1047.	1.5	366
377	The rising prevalence and changing age distribution of multiple sclerosis in Manitoba. <i>Neurology</i> , 2010, 74, 465-471.	1.5	252
378	Validation of a Self-Report Comorbidity Questionnaire for Multiple Sclerosis. <i>Neuroepidemiology</i> , 2010, 35, 83-90.	1.1	138

#	ARTICLE	IF	CITATIONS
379	Impact of loss of mobility on instrumental activities of daily living and socioeconomic status in patients with MS. <i>Current Medical Research and Opinion</i> , 2010, 26, 493-500.	0.9	62
380	Under Treatment of Overactive Bladder Symptoms in Patients With Multiple Sclerosis: An Ancillary Analysis of the NARCOMS Patient Registry. <i>Journal of Urology</i> , 2010, 183, 1432-1437.	0.2	97
381	The prevalence of multiple sclerosis in 3 US communities. <i>Preventing Chronic Disease</i> , 2010, 7, A12.	1.7	55
382	High frequency of adverse health behaviors in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2009, 15, 105-113.	1.4	135
383	Proof of concept studies for tissue-protective agents in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2009, 15, 542-546.	1.4	9
384	Smoking Status over Two Years in Patients with Multiple Sclerosis. <i>Neuroepidemiology</i> , 2009, 32, 72-79.	1.1	21
385	A cross-sectional study of bone health in multiple sclerosis. <i>Neurology</i> , 2009, 73, 1394-1398.	1.5	69
386	Relapses in multiple sclerosis. <i>Neurology</i> , 2009, 73, 1612-1613.	1.5	3
387	Parent-of-origin effect in multiple sclerosis. <i>Neurology</i> , 2009, 73, 602-605.	1.5	34
388	The burden of mental comorbidity in multiple sclerosis: frequent, underdiagnosed, and undertreated. <i>Multiple Sclerosis Journal</i> , 2009, 15, 385-392.	1.4	191
389	Quantile regression and restricted cubic splines are useful for exploring relationships between continuous variables. <i>Journal of Clinical Epidemiology</i> , 2009, 62, 511-517.e1.	2.4	222
390	Comorbidity delays diagnosis and increases disability at diagnosis in MS. <i>Neurology</i> , 2009, 72, 117-124.	1.5	213
391	Effect of Physical Comorbidities on Risk of Depression in Multiple Sclerosis. <i>International Journal of MS Care</i> , 2009, 11, 161-165.	0.4	6
392	An Intervention to Improve Procedure Education for Internal Medicine Residents. <i>Journal of General Internal Medicine</i> , 2008, 23, 288-293.	1.3	57
393	Resting state sensorimotor functional connectivity in multiple sclerosis inversely correlates with transcallosal motor pathway transverse diffusivity. <i>Human Brain Mapping</i> , 2008, 29, 818-827.	1.9	162
394	Evaluation of the six-minute walk in multiple sclerosis subjects and healthy controls. <i>Multiple Sclerosis Journal</i> , 2008, 14, 383-390.	1.4	535
395	You get what you measure. <i>Neurology</i> , 2008, 71, 620-621.	1.5	2
396	Comorbidity, socioeconomic status and multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2008, 14, 1091-1098.	1.4	168



#	ARTICLE	IF	CITATIONS
397	When one and one make three. <i>Neurology</i> , 2008, 70, 1067-1068.	1.5	8
398	Validation of NARCOMS Depression Scale. <i>International Journal of MS Care</i> , 2008, 10, 81-84.	0.4	18
399	Validation of the NARCOMS registry: diagnosis. <i>Multiple Sclerosis Journal</i> , 2007, 13, 770-775.	1.4	111
400	Validity of performance scales for disability assessment in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2007, 13, 1176-1182.	1.4	237
401	Disparities in the management of multiple sclerosis-related bladder symptoms. <i>Neurology</i> , 2007, 68, 1971-1978.	1.5	65
402	Autoimmune disease and multiple sclerosis: methods, methods, methods. <i>Lancet Neurology</i> , The, 2007, 6, 575-576.	4.9	9
403	Functional pathway-defined MRI diffusion measures reveal increased transverse diffusivity of water in multiple sclerosis. <i>NeuroImage</i> , 2006, 32, 1127-1133.	2.1	56
404	Multiple sclerosis and risk-taking. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2006, 99, 63-63.	0.2	1
405	Does multiple sclerosis-associated disability differ between races?. <i>Neurology</i> , 2006, 66, 1235-1240.	1.5	162
406	Drug Insight: interferon treatment in multiple sclerosis. <i>Nature Clinical Practice Neurology</i> , 2006, 2, 34-44.	2.7	38
407	Subjective cognitive complaints relate to mild impairment of cognition in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2005, 11, 69-75.	1.4	73
408	Changes in the ascertainment of multiple sclerosis. <i>Neurology</i> , 2005, 65, 1066-1070.	1.5	80
409	Validation of the NARCOMS Registry: fatigue assessment. <i>Multiple Sclerosis Journal</i> , 2005, 11, 583-584.	1.4	46
410	Validation of the NARCOMS Registry: pain assessment. <i>Multiple Sclerosis Journal</i> , 2005, 11, 338-342.	1.4	39
411	Association of fatigue and brain atrophy in multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2005, 228, 161-166.	0.3	111
412	Clinical characteristics of African Americans vs Caucasian Americans with multiple sclerosis. <i>Neurology</i> , 2004, 63, 2039-2045.	1.5	275
413	Environmental risk factors in multiple sclerosis aetiology. <i>Lancet Neurology</i> , The, 2004, 3, 709-718.	4.9	290
414	Appraisal of the multiple sclerosis functional composite. <i>Expert Review of Neurotherapeutics</i> , 2003, 3, 335-341.	1.4	1



#	ARTICLE	IF	CITATIONS
415	Predictors of alternative medicine use by multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2003, 9, 461-466.	1.4	68
416	Validity and reliability of the MSQ LI in cognitively impaired patients with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2003, 9, 621-626.	1.4	97
417	Multiple Sclerosis and Epstein-Barr Virus. <i>Canadian Journal of Infectious Diseases &amp; Medical Microbiology</i> , 2002, 13, 111-118.	0.3	10
418	Unusual Imaging Findings in Progressive Myoclonus Epilepsy. <i>Epilepsia</i> , 2002, 42, 430-432.	2.6	5
419	Familial Autoimmune Myasthenia Gravis: Four Patients Involving Three Generations. <i>Canadian Journal of Neurological Sciences</i> , 2000, 27, 307-310.	0.3	13
420	Multiple sclerosis and antecedent infections. <i>Neurology</i> , 2000, 54, 2307-2310.	1.5	92
421	The epidemiology of multiple sclerosis. , 0, , 46-55.		0